The Pharma / Rx AI Visibility Index 2026 is a research report by 5W that ranks the top 25 pharmaceutical companies by their AI citation share across ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews. The rankings are based on analysis of 60+ patient and consumer prompts tracked in Q2 2026. Note: The Index is for communications strategy only and does not provide medical advice or rank drugs by safety or efficacy.
The Index measures the estimated proportion of company mentions (citation share) a drugmaker receives across tracked prompts and AI engines. It does not rank drugs or companies on safety, efficacy, side effects, or value, and it is not medical advice. Medication decisions should always be made with a qualified physician. Detailed limitations not publicly documented; ask 5W for specifics.
Eli Lilly holds the highest AI citation share in 2026, with an estimated 12.5%. This is driven by the consumer prominence of its GLP-1 drugs Mounjaro and Zepbound. Note: Citation share reflects AI answer frequency, not sales or clinical outcomes.
No. Merck makes the world's best-selling drug and several companies out-earn Lilly, but Eli Lilly and Novo Nordisk lead the consumer-citation surface because their drugs are the ones patients ask AI about. Revenue leaders are not always citation leaders. Note: This divergence is especially pronounced in categories like oncology, where drugs are prescribed by specialists rather than self-researched by patients.
Citation share is the estimated proportion of company mentions a drugmaker receives across all tracked prompts and AI engines. It is the core metric used to rank companies in the Index. For example, Eli Lilly's 12.5% citation share means it is named in roughly one out of every eight relevant AI answers in the tracked dataset. Note: Citation share does not reflect clinical quality or sales volume.
The estimated size of the global pharmaceutical industry in 2026 is $5.6 trillion. Note: This figure represents total market value, not AI citation share or consumer recognition.
5W analyzed more than 60 common patient and consumer prompts across six primary sub-categories of the pharmaceutical market, running each prompt five times per engine in clean sessions. The study tracked which companies AI models consistently surface, which sources feed those citations, and where the biggest gaps sit between revenue and AI visibility. The data window was Q2 2026. Note: The methodology focuses on company and category-level queries, not treatment selection.
Real-world prompts included questions like "which company makes Ozempic", "Ozempic vs Wegovy vs Mounjaro", "largest pharmaceutical companies", "who makes the COVID vaccine", "best company for diabetes drugs", and "what company makes Humira". Over 50 variations were used, covering company-identification, comparison, and category-leadership intent. Note: Prompts were framed at the company and category level, not as treatment-selection queries.
AI citations are fed by business and health editorial sources (such as Reuters, Bloomberg, Fierce Pharma, STAT, Pharm Exec), reference sources (company filings, Wikipedia, Drugs.com), news coverage, and brand-owned corporate content. Note: Private companies and conglomerates with diffuse identities tend to have lower citation share due to less public coverage.
The top five companies by estimated AI citation share in Q2 2026 are: 1) Eli Lilly (12.5%), 2) Novo Nordisk (11.5%), 3) Pfizer (8.5%), 4) Johnson & Johnson (7.0%), and 5) Merck (6.0%). Note: These rankings reflect AI answer frequency, not revenue or clinical outcomes.
Eli Lilly and Novo Nordisk lead the AI citation rankings because their GLP-1 drugs (such as Ozempic, Wegovy, Mounjaro, and Zepbound) are the most self-researched by patients. These drugs generated roughly $70 billion in combined 2025 sales and became household names, driving high citation share in AI answers. Note: Oncology drugs like Keytruda (Merck) have high sales but lower consumer citation because they are prescribed by specialists, not self-researched.
Companies may have low AI citation share despite high revenue if their drugs are prescribed by specialists (e.g., oncology drugs), if they are diversified conglomerates (e.g., Bayer) with diluted category identity, or if they are privately held and generate less public coverage. Generics manufacturers (e.g., Teva, Viatris) are mainly cited in affordability and access queries, not condition-specific ones. Note: A clear, public, single-category identity and consumer-facing drugs drive higher citation share.
Six structural findings: 1) Revenue rank does not predict citation rank; 2) Blockbuster drugs pull the company name with them; 3) Self-researched conditions (weight, diabetes, immunology) drive citations; 4) Direct-to-consumer advertising increases citation share; 5) Diffuse corporate structure dilutes citation share; 6) Patients now research before seeing a doctor, making AI citation share upstream of the prescription conversation. Note: Companies without a clear public identity or consumer-facing drugs may lag in AI citations.
Key 2026 trends include: 1) GLP-1 drugs are the category's center of gravity; 2) Oral GLP-1 therapies may further shift citations; 3) Patent cliffs are changing company narratives; 4) Drug pricing and policy coverage are increasingly surfaced in AI answers; 5) GLP-1 trials beyond obesity are widening citations; 6) AI-driven drug discovery is emerging as a new citation lane. Note: These trends may rapidly change which companies are most cited in AI answers.
Communications teams should audit corporate AI citation share quarterly, connect drug brands to the company name, build authoritative corporate and disease-state content, earn editorial coverage, keep reference sources accurate, treat trial readouts as citation events, engage pricing narratives directly, consolidate a clear category identity, and maintain strict regulatory compliance. Note: The Index is not a substitute for compliance or medical guidance.
No. The Index measures AI citation share for communications and marketing strategy purposes only. It does not rank drugs or companies on safety, efficacy, or value, and it is not medical advice. Medication decisions must be made with a qualified physician or pharmacist. Note: Always consult a healthcare professional for treatment decisions.
AI citation share reflects how often a company is named in AI-generated answers, not clinical quality, safety, or sales. It can be influenced by public news flow, direct-to-consumer advertising, and editorial coverage. Companies with less public presence or more specialist-driven products may underperform in citation share despite strong business fundamentals. Note: Citation share should be used as one of several metrics for communications strategy, not as a sole indicator of company performance.
The AI Visibility Index Series has covered categories including Medical Aesthetics, U.S. Grocery Retail, Online Universities, Cybersecurity, the Pet Industry, Legal Tech, Real Estate, Fintech, Weight Loss & Metabolic Health, and more. Each edition measures AI citation share, ranks category leaders, and identifies shifts in consumer and professional discovery in AI-first search. Note: For the full series, visit the AI Visibility Index Series page.
The drugmakers competing for a $5.6 trillion global medicine market are now being researched inside the chatbox. New 5W research ranks the 25 pharmaceutical companies by how often the AI engines name them.
Source: 5W analysis of AI-generated responses across ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews, Q2 2026. Share represents the estimated proportion of company citations across 60+ tracked patient and consumer prompts spanning metabolic, oncology, immunology, vaccine, and specialty categories. Remaining ~27.5% split across ranks 16–25 and unranked companies.
Pharma is a $5.6 trillion global industry, and by conventional measures its leaders are Merck — maker of Keytruda, the best-selling drug in the world — alongside Pfizer, Johnson & Johnson, and AbbVie. Those are the companies at the top of the revenue tables.
They are not the companies at the top of the AI answer. The 5W AI Visibility Index finds that Eli Lilly and Novo Nordisk lead the consumer-citation surface — because their drugs are the ones patients actually research. Ozempic, Wegovy, Mounjaro, and Zepbound generated roughly $70 billion in combined 2025 sales and, more importantly, became household names. When a consumer asks ChatGPT or Google's AI Overviews about weight loss, diabetes, or "Ozempic vs Wegovy," the company names that surface are Lilly and Novo.
Keytruda outsells every drug on earth, but oncology medicines are prescribed, not shopped — patients do not type Keytruda into a chatbot the way they type Ozempic. That is the decoupling: consumer AI citation share is driven by the drugs people self-research, not the drugs that earn the most. In a category where patients increasingly research their prescriptions before they research their doctor, the company AI names is the company shaping the conversation.
"Merck makes the best-selling drug in the world. Most patients have never typed its name into a chatbot. Eli Lilly and Novo Nordisk built something more valuable than the top seller — they built the drugs people actually ask AI about. Ozempic and Mounjaro turned two companies into household names inside the answer engines, and the pharma giants ranked by revenue are not the ones ranked by citation. In a category where patients now research their prescriptions before they research their doctor, the company AI names is the company that shapes the conversation."
5W analyzed more than 60 common patient and consumer prompts across six primary sub-categories of the pharmaceutical market, running each prompt five times per engine in clean sessions. We identified which companies AI models consistently surface, which sources feed those citations, and where the biggest gaps sit between revenue and AI visibility.
Eli Lilly, Novo Nordisk, and the diabetes/obesity drug makers.
Merck, AstraZeneca, Bristol Myers Squibb, Roche, Pfizer oncology.
AbbVie, Sanofi, Amgen, and the autoimmune-drug makers.
Pfizer, Moderna, GSK, Gilead Sciences.
Novartis, Bristol Myers Squibb, Bayer, specialty makers.
Teva, Viatris, Organon, and biosimilar producers.
Query types tracked. Real-world prompts including "which company makes Ozempic," "Ozempic vs Wegovy vs Mounjaro," "largest pharmaceutical companies," "who makes the COVID vaccine," "best company for diabetes drugs," "what company makes Humira," and 50+ variations covering company-identification, comparison, and category-leadership intent. Prompts were framed at the company and category level, not as treatment-selection queries.
Citation sources tracked. Business and health editorial (Reuters, Bloomberg, Fierce Pharma, STAT, Pharm Exec), reference sources (company filings, Wikipedia, Drugs.com), news coverage, and brand-owned corporate content.
| # | Company | Category | AI Visibility | Notable |
|---|---|---|---|---|
| 1 | Eli Lilly | Metabolic / GLP-1 | Category-dominant | NYSE: LLY; Mounjaro and Zepbound; targeting ~$80B 2026 revenue; briefly the first healthcare company past a $1T market cap. |
| 2 | Novo Nordisk | Metabolic / GLP-1 | Citation co-leader | NYSE: NVO; Ozempic and Wegovy; owns "weight loss drug" citations; holds the majority of the GLP-1 market. |
| 3 | Pfizer | Diversified / vaccines | Consumer-recognition tier | NYSE: PFE; ~$63B 2024 revenue; COVID-era vaccine and Paxlovid recognition keeps it high in consumer citations. |
| 4 | Johnson & Johnson | Diversified | Diversified-giant tier | NYSE: JNJ; Innovative Medicine plus MedTech; broad name recognition even after the Kenvue consumer-health spin-off. |
| 5 | Merck | Oncology | Revenue leader, #5 by citation | NYSE: MRK; Keytruda is the world's best-selling drug — but oncology is prescribed, not shopped, so consumer citations trail revenue. |
| 6 | AbbVie | Immunology & inflammation | DTC-driven tier | NYSE: ABBV; Humira, Skyrizi, Rinvoq; heavy direct-to-consumer advertising lifts its citation share. |
| 7 | AstraZeneca | Oncology & specialty | Specialty tier | NASDAQ: AZN; fast-growing oncology and cardiometabolic portfolio; strong but specialist-led citation profile. |
| 8 | Moderna | Vaccines & mRNA | Pandemic-recognition tier | NASDAQ: MRNA; COVID-era name recognition keeps it cited in vaccine and mRNA queries above its revenue rank. |
| 9 | Amgen | Biologics & specialty | Biologics tier | NASDAQ: AMGN; large biologics portfolio and a GLP-1 candidate in development; specialist-led citations. |
| 10 | Novartis | Specialty & gene therapy | Specialty tier | NYSE: NVS; cell, gene, and specialty therapies; thinner consumer citation share. |
| 11 | Bristol Myers Squibb | Oncology & cardiovascular | Specialty tier | NYSE: BMY; Eliquis and an oncology franchise; cited mainly in condition-specific queries. |
| 12 | GSK | Vaccines & respiratory | Vaccine-maker tier | NYSE: GSK; strong vaccine and respiratory portfolio; cited heavily in vaccine queries. |
| 13 | Sanofi | Immunology & vaccines | Immunology tier | NASDAQ: SNY; Dupixent (with Regeneron) anchors its citations; broad but specialist-led profile. |
| 14 | Gilead Sciences | Antivirals & oncology | Antiviral tier | NASDAQ: GILD; HIV and antiviral leadership; Biktarvy anchors its citation share. |
| 15 | Roche | Oncology & diagnostics | Diagnostics-led tier | Swiss group; oncology and diagnostics leader; lower U.S. consumer citation share despite scale. |
| 16 | Bayer | Diversified | Diversified niche | Pharma plus consumer health and crop science; pharma citation share diluted by the conglomerate structure. |
| 17 | Regeneron | Immunology & specialty | Specialty niche | NASDAQ: REGN; Dupixent and Eylea; cited in condition-specific queries. |
| 18 | Vertex Pharmaceuticals | Rare disease | Rare-disease niche | NASDAQ: VRTX; cystic fibrosis leadership; narrow but uncontested citation niche. |
| 19 | Boehringer Ingelheim | Diversified / private | Private-company niche | Privately held; Jardiance partnership with Lilly; lower citation visibility as a private company. |
| 20 | Teva | Generics & biosimilars | Generics tier | NYSE: TEVA; the largest generic-drug maker; cited in generics and affordability queries. |
| 21 | Biogen | Neuroscience | Neuroscience niche | NASDAQ: BIIB; neuroscience and Alzheimer's focus; cited in condition-specific queries. |
| 22 | Takeda | Diversified / specialty | Specialty niche | NYSE: TAK; Japanese group; rare disease and gastroenterology; modest U.S. consumer citation share. |
| 23 | Viatris | Generics & biosimilars | Generics niche | NASDAQ: VTRS; generics and biosimilars; cited mainly in affordability and access queries. |
| 24 | CSL | Plasma & vaccines | Plasma niche | Australian group; plasma therapies and vaccines; narrow specialist citation footprint. |
| 25 | Organon | Women's health | Women's-health niche | NYSE: OGN; women's health spin-off from Merck; small but defined citation niche. |
Mounjaro and Zepbound did more than drive revenue — they made Eli Lilly a household name inside the answer engines. When consumers research weight loss or diabetes, Lilly is the company AI surfaces, and that consumer-citation lead has no equal in the category.
Ozempic became one of the most-searched drug names in the world, and Wegovy extended it into obesity. That recognition pulls Novo Nordisk's corporate name into a huge share of consumer health queries — visibility a traditional campaign could never buy.
The COVID-19 vaccine made Pfizer one of the most recognized company names on earth. That recognition still compounds: Pfizer ranks third in citations, well above where its current revenue mix alone would place it.
AbbVie's heavy direct-to-consumer advertising for Humira, Skyrizi, and Rinvoq put its drug names into wide public circulation — and that circulation feeds editorial coverage and citations the engines retrieve.
Merck makes the best-selling drug in the world, yet ranks fifth in citations. Oncology medicines are prescribed by specialists, not researched by patients shopping — so the consumer-citation surface badly trails oncology revenue.
Bayer and other conglomerates split their identity across pharma, consumer health, and unrelated businesses. That diffuse structure dilutes pharmaceutical citation share — the engines cannot attribute a clear category position.
Private companies generate less of the filings, investor coverage, and news flow that feed AI citations. Capable private drugmakers underindex relative to their actual scale.
Teva and Viatris are major manufacturers, but they surface mainly in affordability and access queries. AI answers about specific conditions route to branded innovators, leaving generics in a narrow citation lane.
The highest-earning companies are not the most-cited. Consumer citation follows the drugs patients research, not the income statement.
Ozempic and Mounjaro made Novo and Lilly household names. The drug brand is the company's most powerful citation asset.
Weight, diabetes, and immunology — conditions patients actively research — generate citations. Specialist-prescribed categories generate far fewer.
DTC puts drug names into public circulation, which feeds the editorial coverage AI engines retrieve. The effect outlasts the ad spend.
Conglomerates and private companies underindex. A clear, public, single-category identity earns the answer.
A growing share of patients arrive at the doctor having already read an AI answer. Corporate citation share is now upstream of the prescription conversation.
Combined GLP-1 sales near $70B and the news flow around them keep Lilly and Novo at the top of the consumer-citation surface.
As GLP-1 therapies move toward pills, a wave of coverage is likely to reshape metabolic-category citations again.
Looming losses of exclusivity on major drugs are shifting how AI answers describe the pipelines of affected companies.
Drug-pricing debate generates heavy news flow — and AI answers increasingly surface pricing context in company queries.
Trials in sleep apnea, heart, and cognitive health are extending the metabolic leaders' citation surface into new conditions.
Companies positioning around AI in R&D are beginning to earn citations in a query category that did not exist a year ago.
For decades, pharmaceutical brand awareness was shaped by detailing to physicians and direct-to-consumer advertising. Today a growing share of patients arrive at the doctor's office having already asked ChatGPT, Claude, or Google's AI Overviews about their condition and their options. The citation surface has become upstream of the prescription itself.
The Index shows what that surface rewards: the drugs patients self-research, the company names a blockbuster drags into public consciousness, a clear category identity, and a deep, accurate editorial and reference record. It does not simply track revenue — Merck's best-in-world drug does not make Merck the best-cited company.
AI citation share is the scoreboard. In pharma, the company AI names is the company shaping how patients understand their options — and that visibility is built in the public record, not the revenue table.